Our Brands
Cannassist International seeks to provide exceptional value to our investors with a focus on transparency, communication, and results.
CannAssist International, through a researched based platform, deigns to create higher level alternative therapeutics. Producing effective products that are kinder to the body and free of aggressive side-effects is our goal. We will task our own R&D across many health support targets and work to strategically ally ourselves with other researchers and companies interested in achieving goals aligned with ours. Testing is the cornerstone of our foundation including comparisons to other therapeutic options. Responsible product development and responsible deployment of resources is our unwavering commitment to the consumers we serve.
Our History
Xceptor Labs is founded
Xceptor Labs is formed as a research based OTC pharmaceutical manufacturer. It develops the groundbreaking bioenhanced CBD, CiBiDinol, and becomes a prominent researcher in the cannabinoid space.
CannAssist International Corporation is founded
Seeking to expand beyond raw material production and into finished goods, better funded research, and charitable social programs, CannAssist International is founded as the parent company of Xceptor Labs.
Xceptor Labs launches its pilot CBD brand
CannAssist releases its pilot brand Xceptor CBD which is headlined by the first topical pain cream with CBD to be issued a National Drug Code registered with the FDA.
CannAssist International becomes publicly traded on the OTCQB market under stock symbol (CNSC)
Seeing the value of being the first CBD manufacturer to be publicly traded on the American stock exchanges, CannAssist International is registered on the OTCQB market under the stock symbol (CNSC). CannAssist hopes the required compliance and transparency of our position will allow us to forge new legal pathways for cannabinoid research and sales.
CannAssist officially releases its premier product line, Xceptol.
After a successful pilot launch of the Xceptor CBD brand, CannAssist launches its full line of premium CBD products including capsules, liquid drops, and its' National Drug Code possessing topical pain cream.
Disclaimer
Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.
To install this Web App in your iPhone/iPad press 
and then Add to Home Screen.
